Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

231 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HIV-Selectest enzyme immunoassay and rapid test: ability to detect seroconversion following HIV-1 infection.
Khurana S, Norris PJ, Busch MP, Haynes BF, Park S, Sasono P, Mlisana K, Salim AK, Hecht FM, Mulenga J, Chomba E, Hunter E, Allen S, Nemo G, Rodriguez-Chavez IR; Women's Interagency HIV Study Collaborative Study Group; Margolick JB; Multicenter AIDS Cohort Study (MACS); Golding H. Khurana S, et al. Among authors: golding h. J Clin Microbiol. 2010 Jan;48(1):281-5. doi: 10.1128/JCM.01573-09. Epub 2009 Nov 11. J Clin Microbiol. 2010. PMID: 19906903 Free PMC article.
CCR5 N-terminal region plays a critical role in HIV-1 inhibition by Toxoplasma gondii-derived cyclophilin-18.
Golding H, Khurana S, Yarovinsky F, King LR, Abdoulaeva G, Antonsson L, Owman C, Platt EJ, Kabat D, Andersen JF, Sher A. Golding H, et al. J Biol Chem. 2005 Aug 19;280(33):29570-7. doi: 10.1074/jbc.M500236200. Epub 2005 Jun 23. J Biol Chem. 2005. PMID: 15975927 Free article.
We recently identified structural determinants of C-18 required for anti-HIV activity (Yarovinsky, F., Andersen, J. F., King, L. R., Caspar, P., Aliberti, J., Golding, H., and Sher, A. (2004) J. Biol. Chem. 279, 53635-53642). ...
We recently identified structural determinants of C-18 required for anti-HIV activity (Yarovinsky, F., Andersen, J. F., King, L. R., Caspar, …
Human immunodeficiency virus (HIV) vaccine trials: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies.
Khurana S, Needham J, Mathieson B, Rodriguez-Chavez IR, Catanzaro AT, Bailer RT, Kim J, Polonis V, Cooper DA, Guerin J, Peterson ML, Gurwith M, Nguyen N, Graham BS, Golding H. Khurana S, et al. Among authors: golding h. J Virol. 2006 Mar;80(5):2092-9. doi: 10.1128/JVI.80.5.2092-2099.2006. J Virol. 2006. PMID: 16474117 Free PMC article. Clinical Trial.
Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes.
Khurana S, Needham J, Park S, Mathieson B, Busch MP, Nemo G, Nyambi P, Zolla-Pazner S, Laal S, Mulenga J, Chomba E, Hunter E, Allen S, McIntyre J, Hewlett I, Lee S, Tang S, Cowan E, Beyrer C, Altfeld M, Yu XG, Tounkara A, Koita O, Kamali A, Nguyen N, Graham BS, Todd D, Mugenyi P, Anzala O, Sanders E, Ketter N, Fast P, Golding H. Khurana S, et al. Among authors: golding h. J Acquir Immune Defic Syndr. 2006 Nov 1;43(3):304-12. doi: 10.1097/01.qai.0000242465.50947.5f. J Acquir Immune Defic Syndr. 2006. PMID: 17019363 Free PMC article.
231 results